Compile Data Set for Download or QSAR
Report error Found 92 Enz. Inhib. hit(s) with Target = 'Isoform 4 of cAMP-specific 3',5'-cyclic phosphodiesterase 4A (RD1)'
LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 0.488nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 0.669nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285537(US10077269, Example 10 | 3-(4-chloro-3-fluoro-phen...)
Affinity DataIC50: 1.51nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.77nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 2.91nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285568(US10077269, Example 41 | N-cyclopropyl-3-(3-fluoro...)
Affinity DataIC50: 3.13nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285556(US10077269, Example 29 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 3.48nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285536(US10077269, Example 9 | 3-(4-Chloro-2,5-difluoroph...)
Affinity DataIC50: 3.83nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285576(US10077269, Example 49 | azetidin-1-yl[3-(3-chloro...)
Affinity DataIC50: 4.16nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285626(US10077269, Example 96 | 3-(4-chloro-2,5-difluoro-...)
Affinity DataIC50: 4.58nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285551(US10077269, Example 24 | 4-[2-(azetidin-1-ylcarbon...)
Affinity DataIC50: 5.04nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285540(US10077269, Example 13 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 5.13nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285627(US10077269, Example 97 | 3-(4-chloro-5-fluoro-2-me...)
Affinity DataIC50: 5.48nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285622(US10077269, Example 92 | 3-(4-cyano-2,5-difluoroph...)
Affinity DataIC50: 5.52nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285616(US10077269, Example 86 | azetidin-1-yl[3-(2,2-difl...)
Affinity DataIC50: 5.83nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285613(US10077269, Example 83 | azetidin-1-yl[3-(3,4-dich...)
Affinity DataIC50: 6.21nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285547(US10077269, Example 20 | 4-[2-(azetidin-1-ylcarbon...)
Affinity DataIC50: 6.70nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285603(US10077269, Example 76 | azetidin-1-yl{3-[2-(diflu...)
Affinity DataIC50: 7.09nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285574(US10077269, Example 47 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 7.37nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285611(US10077269, Example 81 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 7.86nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285602(US10077269, Example 75 | N-cyclopropyl-3-[2-(diflu...)
Affinity DataIC50: 10.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285595(US10077269, Example 68 | 3-(4-chloro-2-fluoropheny...)
Affinity DataIC50: 10.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285529(US10077269, Example 2 | 3-(4-Chlorophenyl)-N-cyclo...)
Affinity DataIC50: 10.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285557(US10077269, Example 30 | 3-(4-chlorophenyl)-N-(2-m...)
Affinity DataIC50: 11.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285612(US10077269, Example 82 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 12nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285621(US10077269, Example 91 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 12.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285530(US10077269, Example 3 | Azetidin-1-yl[3-(3,5-diflu...)
Affinity DataIC50: 12.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285539(US10077269, Example 12 | 3-(4-chloro-2-methyl-phen...)
Affinity DataIC50: 14.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285566(US10077269, Example 39 | 3-(1,3-benzoxazol-5-yl)-N...)
Affinity DataIC50: 14.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285550(US10077269, Example 23 | 4-[2-(azetidin-1-ylcarbon...)
Affinity DataIC50: 15.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285573(US10077269, Example 46 | 3-(4-chlorophenyl)-N-[(1R...)
Affinity DataIC50: 15.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285555(US10077269, Example 28 | 3-(3,5-dichlorophenyl)-N-...)
Affinity DataIC50: 15.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285614(US10077269, Example 84 | azetidin-1-yl[3-(3-chloro...)
Affinity DataIC50: 16.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285546(US10077269, Example 19 | 3-(4-cyano-5-fluoro-2-met...)
Affinity DataIC50: 16.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285580(US10077269, Example 53 | azetidin-1-yl[3-(4-fluoro...)
Affinity DataIC50: 17.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285567(US10077269, Example 40 | 3-(4-chloro-2-fluoropheny...)
Affinity DataIC50: 19.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285629(US10077269, Example 99 | 3-(4-cyano-5-fluoro-2-met...)
Affinity DataIC50: 19.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285535(US10077269, Example 8 | Azetidin-1-yl[3-(pyrazolo[...)
Affinity DataIC50: 20nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285620(US10077269, Example 90 | 3-(4-cyano-3-fluorophenyl...)
Affinity DataIC50: 21.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285583(US10077269, Example 56 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 22.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285563(US10077269, Example 36 | 3-(3-chlorophenyl)-N-cycl...)
Affinity DataIC50: 23.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285579(US10077269, Example 52 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 24.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285624(US10077269, Example 94 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 24.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285615(US10077269, Example 85 | 3-(4-chlorophenyl)-N-ethy...)
Affinity DataIC50: 25.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285628(US10077269, Example 98 | 3-(4-cyano-5-fluoro-2-met...)
Affinity DataIC50: 26.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285549(US10077269, Example 22 | N-cyclopropyl-3-(pyrazolo...)
Affinity DataIC50: 27.6nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285577(US10077269, Example 50 | azetidin-1-yl[3-(2,3-dihy...)
Affinity DataIC50: 28.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285561(US10077269, Example 34 | 3-(3-chloro-5-fluoropheny...)
Affinity DataIC50: 29.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285562(US10077269, Example 35 | 3-(3-chloro-5-fluoropheny...)
Affinity DataIC50: 35.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM285597(US10077269, Example 70 | 3-(4-chloro-2-methylpheny...)
Affinity DataIC50: 36.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: